Table 1.
Association between clinical parameters and omental TAM and CLS in 116 advanced stage serous ovarian cancer patients.
| CD68+ om-TAM | CD163+ om-TAM | Ratio of CD68+/CD163+ om-TAM | CD68+ CLS | CD163+ CLS | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Total | High | Low | p Value | High | Low | p Value | High | Low | p Value | Present | Absent | p value | Present | Absent | p Value |
| n= 116 | (n = 59) | (n = 57) | (n = 63) | (n = 53) | (n = 59) | (n = 57) | (n = 31) | (n = 85) | (n = 30) | (n = 86) | ||||||
| Age (y/o) | ||||||||||||||||
| Mean (range) | 57.1 (23~88) | 54.2 (23~88) | 60.1 (36~82) | 0.01 | 55.2 (23~88) | 59.2 (36~82) | 0.09 | 56.6 (30~88) | 57.5 (23~82) | 0.72 | 57.8 (30~82) | 57 (23~88) | 0.71 | 57.8 (30~82) | 56.7 (23~88) | 0.7 |
| BMI | ||||||||||||||||
| Mean (range) | 23 (15~34) | 21 (15~26) | 24 (18~34) | 0.01 | 21 (15~34) | 24 (18~34) | 0.01 | 23 (15~34) | 23 (15~31) | 0.63 | 27 (25~34) | 21 (15~25) | 0.01 | 27 (25~34) | 21 (15~27) | 0.01 |
| FIGO Stage (%) | 1 | 0.77 | 0.39 | 0.18 | 0.18 | |||||||||||
| IIIA | 4 (3) | 0 (0) | 4 (7) | 0 (0) | 4 (8) | 0 (9) | 4 (7) | 0 | 4 (5) | 0 (0) | 4 (5) | |||||
| IIIB | 17 (15) | 11 (19) | 6 (10) | 10 (16) | 7 (12) | 9 (15) | 8 (14) | 4 (13) | 13 (15) | 4 (13) | 13 (15) | |||||
| IIIC | 82 (71) | 41 (70) | 41 (72) | 45 (71) | 37 (70) | 45 (77) | 37 (65) | 26 (84) | 56 (66) | 25 (84) | 57 (66) | |||||
| IVA | 9 (8) | 5 (8) | 4 (7) | 5 (8) | 4 (8) | 3 (5) | 6 (11) | 1 (3) | 8 (9) | 1 (3) | 8 (9) | |||||
| IVB | 4 (3) | 2 (3) | 2 (4) | 3 (5) | 1 (2) | 2 (3) | 2 (3) | 0 (0) | 4 (5) | 0 (0) | 4 (5) | |||||
| Residual Disease (%) | 0.34 | 0.7 | 0.71 | 0.05 | 0.08 | |||||||||||
| Optimal (≤1 cm) | 71 (61) | 39 (66) | 32 (56) | 40 (64) | 31 (58) | 35 (59) | 36 (63) | 14 (45) | 57 (67) | 14 (47) | 57 (66) | |||||
| not-optimal (>1 cm) | 45 (39) | 20 (34) | 25 (44) | 23 (36) | 22 (42) | 24 (41) | 21 (37) | 17 (55) | 28 (33) | 16 (53) | 29 (34) | |||||
| Chemotherapy (%) | 0.002 | 0.006 | 0.44 | 0.006 | 0.006 | |||||||||||
| sensitive | 70 (60) | 45 (76) | 25 (44) | 46 (73) | 24 (45) | 38 (65) | 32 (56) | 11 (35) | 59 (70) | 11 (37) | 59 (69) | |||||
| resistant | 42 (36) | 14 (24) | 28 (49) | 16 (25) | 26 (49) | 19 (32) | 23 (40) | 17 (55) | 25 (29) | 17 (57) | 25 (29) | |||||
| No chemotherapy | 4 (4) | 0 (0) | 4 (7) | 1 (2) | 3 (6) | 2 (3) | 2 (4) | 3 (10) | 1 (1) | 2 (6) | 2 (2) | |||||